Related Experiment Video

Updated: Jul 2, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

The Promise of Chemotherapy-Free Strategies in Advanced Driver-Negative NSCLC: A Systematic Review and Network

Zirui Li1, Weixing Zhao1, Wanjing Guo1

  • 1Department of Oncology, Graduate School of Qinghai University, Xining, Qinghai, China.

Cancer Medicine
|April 9, 2026
PubMed
Abstract

Insights

For advanced driver-negative non-small cell lung cancer (NSCLC), antiangiogenic combinations improve outcomes. Sintilimab + anlotinib offers the best progression-free survival (PFS) with less toxicity, while Endostar + chemotherapy provides the greatest overall survival (OS) benefit.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Antiangiogenic combination therapy is a key strategy for advanced driver-negative NSCLC.
  • This includes combining antiangiogenic agents with immunotherapy and/or chemotherapy.
  • Identifying optimal combinations is crucial for improving patient outcomes.

Purpose of the Study:

  • To conduct a network meta-analysis comparing the efficacy and safety of various antiangiogenic combination therapies.
  • To identify the optimal antiangiogenic combinations for treating advanced driver-negative NSCLC.

Main Methods:

  • Searched major databases (PubMed, Embase, Web of Science, Cochrane Library) for relevant randomized controlled trials (RCTs).
  • Included nine treatment regimens involving 5954 patients.
  • Primary outcomes assessed were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and treatment-related adverse events (TRAEs).

Main Results:

  • Sintilimab + anlotinib showed the best PFS benefit and lowest grade ≥3 TRAEs.
  • Endostar + chemotherapy demonstrated the greatest OS benefit.
  • Atezolizumab + bevacizumab + chemotherapy combination yielded the highest ORR.
  • Regimens combining immunotherapy, antiangiogenic agents, and chemotherapy generally offered the greatest PFS and OS benefits.

Conclusions:

  • Antiangiogenic combinations significantly improve outcomes in driver-negative advanced NSCLC.
  • Specific combinations like Endostar + chemotherapy (OS), atezolizumab-bevacizumab-chemotherapy (ORR), and sintilimab-anlotinib (PFS, safety) show distinct advantages.
  • Treatment selection should be individualized, considering clinical factors and the need for multiethnic trial validation.
Keywords:
antiangiogenic therapynetwork meta‐analysisnon‐small cell lung canceroverall survivalprogression‐free survivalsafety

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...